Here's a Quick Look Into the Fundamentals of Illumina Stock

By Blake Campbell • Saturday, May 18 15:12 • Permanent Link

Illumina sank -3.0% today, compared to the S&P 500's day change of 0.0%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:

Illumina has moved -46.8% over the last year, and the S&P 500 logged a change of 26.5%
ILMN has an average analyst rating of hold and is -26.42% away from its mean target price of $150.96 per share
Its trailing earnings per share (EPS) is $-8.15
Illumina has a trailing 12 month Price to Earnings (P/E) ratio of -13.6 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $2.55 and its forward P/E ratio is 43.6
The company has a Price to Book (P/B) ratio of 3.08 in contrast to the S&P 500's average ratio of 2.95
Illumina is part of the Health Care sector, which has an average P/E ratio of 30.21 and an average P/B of 4.08
The company has a free cash flow of $700.12 Million, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.